Viridian Therapeutics Reports Q3 2026 Results Driven by Lumvoa Commercial Launch
Viridian Therapeutics (VRDN) reported third-quarter 2026 financial results highlighted by the first full quarter of sales for its thyroid eye disease therapy, Lumvoa. The company achieved net product revenue of $24.7 million and successfully reached over 100 patients on therapy as of September 30, 2026. While the company reported a widening net loss of $101.2 million due to increased commercial launch expenses, management emphasized a strong liquidity position with $955.2 million in cash and marketable securities. Commercial progress is supported by a 90% payer engagement rate and an upcoming permanent J-code assignment from CMS effective January 2027, which is expected to streamline reimbursement. Looking ahead, Viridian plans to submit a Biologics License Application for subcutaneous elegrobart in Q1 2027 and expects to disclose data for its FcRn inhibitor, VRDN-008, later this year.
Tickers: $VRDN
Topics: net loss product launch R&D expenses reimbursement revenue
Read the full article at Motley Fool
Part of the story Vera Therapeutics Reports Q3 2026 Results Following TRUTAKNA Commercial Launch (9 articles)